Just caught Inspire Medical Systems (INSP) getting hit hard this morning - down 8.7% after their 2026 guidance came in weaker than expected. Pretty interesting actually because they just crushed Q4 earnings numbers, but the market completely ignored that and focused on the revenue miss instead. This is exactly why medical trades can be so volatile.

The real issue seems to be these new billing code changes for their Inspire V procedure. Basically, doctors are gonna get paid less for the treatment, which creates uncertainty around adoption rates going forward. They had a similar drop 21 days ago (12.4%) when billing code concerns first popped up. So this isn't exactly a surprise, but apparently investors are still digesting what it means.

Looking at the numbers - INSP is trading at $59.97 right now, which is 69.5% below the $196.61 high from February 2025. Down 35% just this year. The stock has been crazy volatile with 32 moves over 5% in the last year alone. This kind of medical trades action is exactly what you get when regulatory uncertainty hits a company's main revenue driver.

The thing is, when quality companies get hit this hard on a single guidance miss, sometimes it creates an opportunity. But that billing code situation needs to stabilize first. Investors who got in early on this one five years ago are looking at a rough ride - a $1,000 investment back then would be worth around $253 now.